Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
APLS Stock Chart & Stats
$23.63
-$1.37(-3.96%)
At close: 4:00 PM EST
$23.63
-$1.37(-3.96%)
Day’s Range― - ―
52-Week Range$16.10 - $35.72
Previous CloseN/A
Volume215.04K
Average Volume (3M)2.84M
Market Cap
$2.99B
Enterprise Value$2.94B
Total Cash (Recent Filing)$479.17M
Total Debt (Recent Filing)$475.37M
Price to Earnings (P/E)79.6
Beta0.89
Next Earnings
Mar 04, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding126,525,215
10 Day Avg. Volume2,101,707
30 Day Avg. Volume2,842,391
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)17.30
Price to Sales (P/S)5.06
P/FCF Ratio-44.79
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit3.26
Enterprise Value/Ebitda31.47
Forecast
1Y Price Target
$38.14Price Target Upside61.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.26
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Growth ExpectationsManagement expects a total of 225 or more patient start forms for Empaveli by year-end, suggesting steadier growth.
Market LeadershipManagement emphasized that Syfovre continues to maintain market leadership, accounting for ~52% of new patient starts in the quarter and >60% of total GA market share.
Medical ValidationThe publication in a prestigious medical journal further validates the impressive efficacy demonstrated by Empaveli in VALIANT.
Bears Say
Market HeadwindsSyfovre's sluggish growth is driven by a persistent funding gap at co-pay assistance foundations, negatively impacting revenue.
Revenue ChallengesSyfovre revenue has been flattish, and the current launch is heading into a 'high-scatter' indication where patient-finding may be a challenge.
Stock PressureOngoing co-pay issues are putting significant pressure on APLS shares.
Apellis Pharmaceuticals News
APLS FAQ
What was Apellis Pharmaceuticals Inc’s price range in the past 12 months?
Apellis Pharmaceuticals Inc lowest stock price was $16.10 and its highest was $35.72 in the past 12 months.
What is Apellis Pharmaceuticals Inc’s market cap?
Apellis Pharmaceuticals Inc’s market cap is $2.99B.
When is Apellis Pharmaceuticals Inc’s upcoming earnings report date?
Apellis Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 86 days.
How were Apellis Pharmaceuticals Inc’s earnings last quarter?
Apellis Pharmaceuticals Inc released its earnings results on Oct 30, 2025. The company reported $1.67 earnings per share for the quarter, beating the consensus estimate of $1.579 by $0.091.
Is Apellis Pharmaceuticals Inc overvalued?
According to Wall Street analysts Apellis Pharmaceuticals Inc’s price is currently Undervalued.
Does Apellis Pharmaceuticals Inc pay dividends?
Apellis Pharmaceuticals Inc does not currently pay dividends.
What is Apellis Pharmaceuticals Inc’s EPS estimate?
Apellis Pharmaceuticals Inc’s EPS estimate is -0.37.
How many shares outstanding does Apellis Pharmaceuticals Inc have?
Apellis Pharmaceuticals Inc has 126,525,215 shares outstanding.
What happened to Apellis Pharmaceuticals Inc’s price movement after its last earnings report?
Apellis Pharmaceuticals Inc reported an EPS of $1.67 in its last earnings report, beating expectations of $1.579. Following the earnings report the stock price went down -31.015%.
Which hedge fund is a major shareholder of Apellis Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in APLS
Apellis Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.14 (61.40% Upside)
$38.14 (61.40% Upside)
Blogger Sentiment
Bullish
APLS Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 17.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $806.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.35%
12-Months-Change
Fundamentals
Return on Equity
14.10%
Trailing 12-Months
Asset Growth
17.39%
Trailing 12-Months
Company Description
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
APLS Company Deck
APLS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected significant progress with the FDA approval of EMPAVELI and strong market leadership of SYFOVRE. However, challenges in SYFOVRE revenue due to free drug programs and operational challenges in patient access were notable concerns.View all APLS earnings summariesAPLS Stock 12 Month Forecast
Average Price Target
$38.14
▲(61.40% Upside)
Technical Analysis
Zai Lab
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
Mirum Pharmaceuticals
―
MoonLake Immunotherapeutics
―
Ownership Overview
3.17% Insiders
18.42% Mutual Funds
41.80% Other Institutional Investors
22.27% Public Companies and Individual Investors